Abstract:Prostate cancer (PCa) is a most common cause of cancer-related death in men. While it develops to metastatic stage, the treatment options are limited. Hence, it desires in vivo models to test novel strategies for treating PCa. Current murine models of prostate cancer need long time for the diseases to progress to an invasive and metastatic cancer. Here, we combined AAV delivery and CRISPR-Cas9 technology to mutate several genes simultaneously in the mouse prostate. Four weeks after delivering of engineered virus, benign prostatic intraepithelial neoplasia (PIN) can be achieved and within eight weeks, the tumor developed to an extremely aggressive cancer. Surprisingly, a basic virus, engineering quintuple gRNAs of Cas9 including Pten, Trp53 and Rb1 induced a primary tumor without formation of metastasis. While adding triple gRNAs targeting epigenetic factors to the basic viral vector, all mice developed lung metastasis with metastasis started to appear after 6 weeks. Castration of the tumor baring mice 5 weeks after initiation did not alter primary tumor and metastasis formation, indicating the metastatic castration-resistant prostate cancer (mCRPC) nature of the model. To reveal the molecular mechanism for cancer progression and metastasis formation, whole genome sequencing (WGS) were performed on lung metastasis samples in combination with mRNA-seq on primary and secondary tumors from the two groups and PBS-injected mice control. Up to 5,000 mutations were accumulated in the genome, although the number varied across the metastatic samples, which were mainly due to chromosome 6 and 8 and revealed heterogeneity of the tumors. Among it, novel key mutations were identified, which will be addressed in the future. Tumor cell plasticity, including epithelial-mesenchymal transition and de-differentiation, were conformed. A short 100kb genomic window at mouse chr5 was captured and found to be sensitive to mutation status of an epigenetic factor. This window is highly conserved to a region at human chr4 and in vitro work confirm evolutionary preserved mechanism. Finally, p-Src/p-Lyn-cMyc related pathways showed clear difference between the two primary tumors with and without metastasis potency. Overall, our model of mCRPC can provide very diverse angles to the initiation and progression of prostate cancer. Furthermore, this model can be used to rapidly verify ideas and hypothesis regarding the mechanism behind the disease, and to test the treatment strategies in vivo in both pre-clinic studies and pharmacy field. Citation Format: Huiqiang Cai, Bin Zhang, Johanne Ahrenfeldt, Nicolai Birkbak, Martin Thomsen. Modelling the metastatic castration-resistant prostate cancer in mice by orthotopic delivering multiplexed gRNAs of CRISPR/Cas9 based on AAV system [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 924.

CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel essential gene in prostate cancer metastasis

CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expression

Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer

Data from Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer

Depletion of the Proteasome Subunit Psma7 Inhibits Colorectal Cancer Cell Tumorigenicity and Migration

Genome-Wide CRISPR-Cas9 Screening and Identification of Potential Genes Promoting Prostate Cancer Growth and Metastasis

Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer

Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer

Use of a navigable interface for integrated whole genome and transcriptome sequencing as a platform for pursuit of therapeutic targets in advanced prostate cancers.

Inhibition of prostate cancer growth and metastasis using small interference RNA specific for minichromosome complex maintenance component 7

Integrative analysis of transcriptomic and metabolomic profiles reveals enhanced arginine metabolism in androgen-independent prostate cancer cells

Identification of PRMT5 as a therapeutic target in cholangiocarcinoma

Inhibition of PRMT5 moderately suppresses prostate cancer growth in vivo but enhances its response to immunotherapy

Protein Arginine Methyltransferases Refine the Classification of Clear Cell Renal Cell Carcinoma with Distinct Prognosis and Tumor Microenvironment Characteristics.

Abstract 924: Modelling the metastatic castration-resistant prostate cancer in mice by orthotopic delivering multiplexed gRNAs of CRISPR/Cas9 based on AAV system

PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma

In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis

Single cell-transcriptomic analysis informs the lncRNA landscape in metastatic castration resistant prostate cancer

Targeting INMT and interrupting its methylation pathway for the treatment of castration resistant prostate cancer

PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast Cancer

Abstract LB446: Decoding the mechanism of metastasis: A novel CAF-therapy that blocks the tumor microenvironment and reverses metastatic traits in all solid tumors